

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. §371**

MERCK 2393

U.S. APPLICATION NO. (If known, see 37 CFR §1.5)

10/088676

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PCT/EP00/08837

11 SEPTEMBER 2000

PRIORITY DATE CLAIMED

23 SEPTEMBER 1999

TITLE OF INVENTION

HEPARANASE-2, A MEMBER OF THE HEPARANASE PROTEIN FAMILY

APPLICANT(S) FOR DO/EO/US

DÜCKER, Klaus, et al

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
 2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
 3. ☒ This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
 4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
 5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
 6. ☒ A translation of the International Application into English (35 U.S.C. §371(c)(2)).
 7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
 8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. §371(c)(3)).
 9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)).
 10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).
- Items 11. to 16. below concern document(s) or information included:**
11. ☐ An Information Disclosure Statement under 37 C.F.R. §§1.97 and 1.98.
 12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. §§3.28 and 3.31 is included.
 13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
 14. ☐ A substitute specification.
 15. ☐ A change of power of attorney and/or address letter.
 16. ☐ Other items or information:

U.S. APPLICATION NO. (if known, see 37 CFR §1.5)

107 088676

INTERNATIONAL APPLICATION NO.

PCT/EP00/08837

ATTORNEY'S DOCKET NUMBER

MERCK 2393

17. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR §1.492 (a) (1) - (5)):**

Search Report has been prepared by the EPO or JPO..... \$890.00

International preliminary examination fee paid to USPTO (37 CFR §1.482)..... \$710.00

No international preliminary examination fee paid to USPTO (37 CFR §1.482)
but international search fee paid to USPTO (37 CFR §1.445(a)(2))..... \$740.00

Neither international preliminary examination fee (37 CFR §1.482) nor
international search fee (37 CFR §1.445(a)(2)) paid to USPTO..... \$1040.00

International preliminary examination fee paid to USPTO (37 CFR §1.482)
and all claims satisfied provisions of PCT Article 33(2)-(4)..... \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$890.00

Surcharge of **\$130.00** for furnishing the oath or declaration later than
months from the earliest claimed priority date (37 C.F.R. §1.492(e)).

☐ 20 ☐ 30

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	11 - 20 =	0	x \$ 18.00
Independent claims	2 - 3 =	0	x \$ 84.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 280.00

TOTAL OF ABOVE CALCULATIONS =

\$890.00

Reduction of 1/2 for filing by small entity, if applicable. A Verified Small Entity Statement must also be

SUBTOTAL =

\$890.00

Processing fee of **\$130.00** for furnishing the English translation later than
months from the earliest claimed priority date (37 C.F.R. §1.492(f)).

☐ 20 ☐ 30
TOTAL NATIONAL FEE =

\$890.00

Fee for recording the enclosed assignment (37 C.F.R. §1.21(h)). The assignment must be accompanied by
an appropriate cover sheet (37 C.F.R. §§3.28, 3.31). \$40.00 per property.

TOTAL FEES ENCLOSED =

\$890.00

Amount to be
refunded:

charged:

a. ☒ A check in the amount of \$890.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 13-3402 in the amount of \$_____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to
Deposit Account No. 13-3402. A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 C.F.R. §§1.494 or 1.495 has not been met, a petition to
revive (37 C.F.R. §1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO: Customer Number 23,599
PATENT TRADEMARK OFFICE



23599

Filed: 21 MARCH 2002

AJZ:kmo

SIGNATURE

Anthony J. Zelano

NAME

27,969

REGISTRATION NUMBER

FORM PTO-1390
(REV 10-95)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. §371**

MERCK 2393

U.S. APPLICATION NO. (If known, see 37 CFR §1.5)

10/088676

INTERNATIONAL APPLICATION NO.

PCT/EP00/08837

INTERNATIONAL FILING DATE

11 SEPTEMBER 2000

PRIORITY DATE CLAIMED

23 SEPTEMBER 1999

TITLE OF INVENTION

HEPARANASE-2, A MEMBER OF THE HEPARANASE PROTEIN FAMILY

APPLICANT(S) FOR DO/EO/US

DÜCKER, Klaus, et al

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. §371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. §371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 C.F.R. §§1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. §§3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
 ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

COPY

U.S. APPLICATION NO. (if known, see 37 CFR §1.5) <div style="font-size: 2em; font-weight: bold; margin-left: 50px;">107 088676</div>		INTERNATIONAL APPLICATION NO. PCT/EP00/08837		ATTORNEY'S DOCKET NUMBER MERCK 2393	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR §1.492 (a) (1) - (5)): Search Report has been prepared by the EPO or JPO..... \$890.00 International preliminary examination fee paid to USPTO (37 CFR §1.482)..... \$710.00 No international preliminary examination fee paid to USPTO (37 CFR §1.482) but international search fee paid to USPTO (37 CFR §1.445(a)(2))..... \$740.00 Neither international preliminary examination fee (37 CFR §1.482) nor international search fee (37 CFR §1.445(a)(2)) paid to USPTO..... \$1040.00 International preliminary examination fee paid to USPTO (37 CFR §1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)..... \$100.00				CALCULATIONS PTO USE ONLY 	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 C.F.R. §1.492(e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30					
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	11 - 20 =	0	x \$ 18.00	\$0.00	
Independent claims	2 - 3 =	0	x \$ 84.00	\$0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 280.00		
TOTAL OF ABOVE CALCULATIONS =				\$890.00	
Reduction of 1/2 for filing by small entity, if applicable. A Verified Small Entity Statement must also be					
SUBTOTAL =				\$890.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 C.F.R. §1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30					
TOTAL NATIONAL FEE =				\$890.00	
Fee for recording the enclosed assignment (37 C.F.R. §1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§3.28, 3.31). \$40.00 per property.					
TOTAL FEES ENCLOSED =				\$890.00	
				Amount to be refunded:	
				charged:	

- a. ☒ A check in the amount of \$890.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. 13-3402 in the amount of \$_____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 13-3402. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 C.F.R. §§1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. §1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO: Customer Number 23,599

PATENT TRADEMARK OFFICE



23599

Filed: 21 MARCH 2002

AJZ:kmo

SIGNATURE

Anthony J. Zelano

NAME

27.969

REGISTRATION NUMBER

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP00/08837
International Filing Date : 11 SEPTEMBER 2000
Priority Date(s) Claimed : 23 SEPTEMBER 1999
Applicant(s) (DO/EO/US) : DÜRCKER, Klaus, et al.

Title: HEPARANASE-2, A MEMBER OF THE HEPARANASE PROTEIN FAMILY

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

SIR:

Prior to calculating the national fee, and prior to examination in the National Phase of the above-identified International application, please amend as follows:

IN THE CLAIMS:

7. (Amended) A recombinant host cell comprising the expression vector of an expression system comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell or a membrane thereof expressing the polypeptide of claim 1.

8. (Amended) A process for producing an isolated polypeptide selected from one of the groups consisting of:

(a) an isolated polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO:1;

(b) an isolated polypeptide comprising a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

(c) an isolated polypeptide having at least 95% identity to the polypeptide sequence of SEQ ID NO:2; and

(d) the polypeptide sequence of SEQ ID NO:2 and

(e) fragments and variants of such polypeptides in (a) to (d).

and comprising the step of culturing a host cell as defined in claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.


10. (Amended) An antibody immunospecific for the polypeptide of claim 1.

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings to Show Changes Made**".

Respectfully submitted,



Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicants
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Boulevard, Suite 1400
Arlington, VA 22201
Direct Dial: 703-812-5311
Facsimile: 703-243-6410
Email: zelano@mwzb.com

AJZ:kmo

Filed: 21 March 2202

VERSION WITH MAKINGS TO SHOW CHANGES MADE

Claims 7,8 and 10 were amended as follows:

7. (Amended) A recombinant host cell comprising the expression vector of an expression system comprising a polynucleotide capable of producing a polypeptide of claim 61 when said expression vector is present in a compatible host cell or a membrane thereof expressing the polypeptide of claim 1.

8. (Amended) A process for producing a polypeptide of claim 1 an isolated polypeptide selected from one of the groups consisting of:

- (a) an isolated polypeptide encoded by a polynucleotide comprising thesequence of SEQ ID NO:1;
- (b) an isolated polypeptide comprising a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;
- (c) an isolated polypeptide having at least 95% identity to the polypeptide sequence of SEQ ID NO:2; and
- (d) the polypeptide sequence of SEQ ID NO:2 and
- (e) fragments and variants of such polypeptides in (a) to (d).

and comprising the step of culturing a host cell as defined in claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

10. (Amended) An antibody immunospecific for the polypeptide of ~~any of one~~ claims 1 to 3.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number
WO 01/21814 A1

(51) International Patent Classification⁷: C12N 15/56,
15/62, 9/24, C07K 16/40, C12Q 1/68, A61K 38/47, 48/00,
G01N 33/50

(72) Inventors; and
(75) Inventors/Applicants (for US only): DÜCKER, Klaus
[DE/DE]; Ettesterstrasse 5, 64291 Darmstadt (DE). SIR-
RENBURG, Christian [DE/DE]; Heinrich-Delp-Strasse
221, 64297 Darmstadt (DE).

(21) International Application Number: PCT/EP00/08837

(22) International Filing Date:
11 September 2000 (11.09.2000)

(74) Common Representative: MERCK PATENT GMBH;
64271 Darmstadt (DE).

(25) Filing Language: English

(81) Designated States (national): CA, JP, US.

(26) Publication Language: English

(84) Designated States (regional): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).


(30) Priority Data:
99118805.3 23 September 1999 (23.09.1999) EP
00114649.7 7 July 2000 (07.07.2000) EP

Published:
— With international search report.

(71) Applicant (for all designated States except US): MERCK
PATENT GMBH [DE/DE]; Frankfurter Strasse 250,
64293 Darmstadt (DE).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: HEPARANASE-2, A MEMBER OF THE HEPARANASE PROTEIN FAMILY



(57) Abstract: Heparanase-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing heparanase-2 polypeptides and polynucleotides in diagnostic assays.

2/1/02

10/088676

PCT/EP00/03337

JC13 Rec'd PCT/PTO 21 MAR 2002

HEPARANASE-2, A MEMBER OF THE HEPARANASE PROTEIN FAMILY

Field of the Invention

This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides sometimes hereinafter referred to as „heparanase-2“, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

Background of the Invention

The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superceding earlier approaches based on "positional cloning". A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

Summary of the Invention

The present invention relates to heparanase-2, in particular heparanase-2 polypeptides and heparanase-2 polynucleotides, recombinant materials and methods for their production. Such polypeptides and polynucleotides are of interest in relation to methods of treatment of certain diseases, including, but not limited to, autoimmune disorders, blood coagulation

disorders, cancer, diabetes, ischemia, sepsis and stroke, cardiovascular diseases, thrombosis, hereinafter referred to as "diseases of the invention". In a further aspect, the invention relates to methods for identifying agonists and antagonists (e.g., inhibitors) using the materials provided by the invention, and treating conditions associated with heparanase-2 imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate heparanase-2 activity or levels.

Description of the Invention

In a first aspect, the present invention relates to heparanase-2 polypeptides. Such polypeptides include:

- (a) an isolated polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO:1;
- (b) an isolated polypeptide comprising a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;
- (c) an isolated polypeptide comprising the polypeptide sequence of SEQ ID NO:2;
- (d) an isolated polypeptide having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;
- (e) the polypeptide sequence of SEQ ID NO:2; and
- (f) an isolated polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence of SEQ ID NO:2;
- (g) fragments and variants of such polypeptides in (a) to (f).

Polypeptides of the present invention are believed to be members of the endoglucuronidase family of polypeptides. Heparan sulfate proteoglycans (HSPGs) are ubiquitous macromolecules of cell surfaces, basement membranes and the extracellular matrix (ECM). They play a major role in cell-cell and cell-extracellular matrix interactions. HSPGs

have been reported to bind to a variety of different molecules like growth factors (e.g. fibroblast growth factors and platelet-derived growth factor), cytokines (e.g. interleukin-2), extracellular matrix proteins (e.g. fibronectin, laminin, collagen), factors involved in blood coagulation (e.g. antithrombin III), and other proteins such as lipoproteins, DNA topoisomerases, and β -amyloid proteins (Kjellen, L. and Lindahl, U., Annu. Rev. Biochem. 60, 443-475 (1991); Wight, T.N. et al., Curr. Opin. Cell Biol. 4, 793-801 (1992)).

Binding of signalling molecules to HSPGs leads to their sequestration, thereby creating a localised, readily accessible depot of these bound molecules, which can easily be released upon degradation of HSPGs (Nissen, N. et al., Biochem. J. 338, 637-642 (1999)). Additionally HSPGs are important structural components of the ECM. In capillaries they are found mainly in the subendothelial basement membrane, where they support the vascular endothelium and stabilise the structure of the capillary wall. Expression of heparan sulfate (HS)-degrading endoglucuronidases, commonly called 'heparanases' (Nakajima, M. et al., J. Biol. Chem. 259, 2283-2290 (1984)), is found in blood borne cells and placental trophoblasts, reflecting their requirement for cell diapedesis activity associated with inflammatory processes or wound healing, and pregnancy, respectively (Vlodavsky, I. et al., Invasion Metastasis 12, 112-127 (1992); Goshen, R. et al., Mol. Hum. Reprod. 2, 679-684 (1996)).

Degradation of the HS moieties of HSPGs affects a great variety of biological processes. Of particular interest is the proposed function of heparanases in neoangiogenesis and metastasis, associated with malignant tumours. It has been shown that secreted heparanase activity induces endothelial mitogenesis (Folkman, J. et al., Am. J. Pathol. 13, 393-400 (1988); Ishai-Michaeli, R. et al., Cell. Regul. 1, 833-842 (1990)) and is directly correlating with the metastatic property of a number of human metastatic cell lines as well as specimens of human breast, colon and liver carcinomas (Nakajima, M. et al., Science 220, 611-613 (1983); Vlodavsky, I. et al., Cancer Res. 43, 2704-2711 (1983)).

Biochemical experiments identified so far three distinct groups of heparanase activities, with molecular weights of 137 kDa (Oosta, HG.M.

et al., J. Biol. Chem. 257, 11249-11255 (1982)), 50 kDa (Freeman, C. and Parish, C.R., Biochem. J. 330, 1341-13509 (1998)), and 32-40 kDa (Hoogewerf, A.J. et al., J. Biol. Chem. 270, 3268-3277 (1995)). The first mammalian heparanase gene representing the 50 kDa class (Vlodavsky, I. et al., Nat. Medicine 5, 793-802 (1999); Hulett, M.D. et al., Nat. Medicine 5, 803-809 (1999); Toyoshima M. and Nakajima M., J. Biol. Chem. 270, 24153-24160 (1999)). The heparanase gene is preferentially expressed in highly metastatic mouse and human cell lines and in biopsy specimen of human tumours. Moreover, increased levels of heparanase were detected in sera (Nakajima, M. et al., Science 220, 611-613, (1983)) and urine of metastatic tumour-bearing animals and cancer patients (Vlodavsky, I. et al., Nat. Medicine 5, 793-802 (1999)). Transfection of low or non-metastatic tumour cell lines with the heparanase gene confers a high metastatic potential in experimental mice, resulting in an increased rate of mortality. On the contrary, treatment of experimental animals with heparanase inhibitors (e.g., non-anticoagulant species of low-molecular-weight heparin and polysulfated saccharides) considerably reduces the incidence of lung metastases by melanoma, Lewis lung carcinoma and mammary adenocarcinoma cells (Vlodavsky I. et al., Invasion Metastasis 14, 290-302 (1995), Parish, C.R. et al., Int. J. Cancer 40, 511-517 (1987)). As it is generally accepted that heparanase activity plays a crucial role in many distinct biological processes, there is a clear need to identify further members of this protein family

The biological properties of the heparanase-2 are hereinafter referred to as "biological activity of heparanase-2" or "heparanase-2 activity". Preferably, a polypeptide of the present invention exhibits at least one biological activity of heparanase-2.

Polypeptides of the present invention also includes variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.

Preferred fragments of polypeptides of the present invention include an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO: 2, or an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of SEQ ID NO: 2. Preferred fragments are biologically active fragments that mediate the biological activity of heparanase-2, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.

Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention. The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence that contains secretory or leader sequences, pro-sequences, sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.

Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation from naturally occurring sources, from genetically engineered host cells comprising expression systems (*vide infra*) or by chemical synthesis, using for instance automated peptide synthesizers, or a combination of such methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to heparanase-2 polynucleotides. Such polynucleotides include:

(a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide sequence of SEQ ID NO:1;

(b) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1;

(c) an isolated polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide of SEQ ID NO:1;

(d) the isolated polynucleotide of SEQ ID NO:1;

(e) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;

(f) an isolated polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2;

(g) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;

(h) an isolated polynucleotide encoding the polypeptide of SEQ ID NO:2;

(i) an isolated polynucleotide having or comprising a polynucleotide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polynucleotide sequence of SEQ ID NO:1;

(j) an isolated polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence of SEQ ID NO:2; and

polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

Preferred fragments of polynucleotides of the present invention include an isolated polynucleotide comprising a nucleotide sequence having at least 15, 30, 50 or 100 contiguous nucleotides from the sequence of SEQ ID NO: 1, or an isolated polynucleotide comprising a sequence having at least 30, 50 or 100 contiguous nucleotides truncated or deleted from the sequence of SEQ ID NO: 1.

Preferred variants of polynucleotides of the present invention include splice variants, allelic variants, and polymorphisms, including

polynucleotides having one or more single nucleotide polymorphisms (SNPs).

Polynucleotides of the present invention also include polynucleotides encoding polypeptide variants that comprise the amino acid sequence of SEQ ID NO:2 and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acid residues are substituted, deleted or added, in any combination.

In a further aspect, the present invention provides polynucleotides that are RNA transcripts of the DNA sequences of the present invention. Accordingly, there is provided an RNA polynucleotide that:

- (a) comprises an RNA transcript of the DNA sequence encoding the polypeptide of SEQ ID NO:2;
- (b) is the RNA transcript of the DNA sequence encoding the polypeptide of SEQ ID NO:2;
- (c) comprises an RNA transcript of the DNA sequence of SEQ ID NO:1; or
- (d) is the RNA transcript of the DNA sequence of SEQ ID NO:1;

and RNA polynucleotides that are complementary thereto.

The polynucleotide sequence of SEQ ID NO:1 shows homology with AF144325 (Vlodavsky, I. et al., Nat. Medicine 5, 793-802(1999)). The polynucleotide sequence of SEQ ID NO:1 is a cDNA sequence that encodes the polypeptide of SEQ ID NO:2. The polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence of SEQ ID NO:1 or it may be a sequence other than SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The polypeptide of the SEQ ID NO:2 is related to other proteins of the endoglucuronidase family, having homology and/or structural similarity with AAD42342 (Vlodavsky, I. et al., Nat. Medicine 5, 793-802(1999)).

Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one heparanase-2 activity.

Polynucleotides of the present invention may be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA in cells of human bladder, (see for instance, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Polynucleotides that are identical, or have sufficient identity to a polynucleotide sequence of SEQ ID NO:1, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR). Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic

clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than human) that have a high sequence similarity to SEQ ID NO:1, typically at least 95% identity. Preferred probes and primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50, if not at least 100 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process comprising the steps of screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100, obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof, preferably of at least 15 nucleotides.

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide does not extend all the way through to the 5' terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during first strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., Proc Nat Acad Sci USA 85, 8998-

9002, 1988). Recent modifications of the technique, exemplified by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark) technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analysed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook *et al.* (*ibid*). Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector that is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, (*ibid*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic

interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and/or purification.

Polynucleotides of the present invention may be used as diagnostic reagents, through detecting mutations in the associated gene. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO:1 in the cDNA or genomic sequence and which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques well known in the art.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or it may be amplified enzymatically by using PCR, preferably RT-PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled heparanase-2 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401).

An array of oligonucleotides probes comprising heparanase-2 polynucleotide sequence or fragments thereof can be constructed to conduct efficient screening of *e.g.*, genetic mutations. Such arrays are preferably high density arrays or grids. Array technology methods are well

known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M.Chee et al., Science, 274, 610-613 (1996) and other references cited therein.

5 Detection of abnormally decreased or increased levels of polypeptide or mRNA expression may also be used for diagnosing or determining susceptibility of a subject to a disease of the invention. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit comprising:

- 20 (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment or an RNA transcript thereof;
- (b) a nucleotide sequence complementary to that of (a);
- (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2 or a fragment thereof; or
- 25 (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly diseases of the invention, amongst others.

30 The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequence is specifically targeted to,

and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping (Walter, M. Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P., (1994) A method for constructing radiation hybrid maps of whole genomes, Nature Genetics 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the GeneBridge4 RH panel (Hum Mol Genet 1996 Mar;5(3):339-46 A radiation hybrid map of the human genome. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud'Homme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To determine the chromosomal location of a gene using this panel, 93 PCRs are performed using primers designed from the gene of interest on RH DNAs. Each of these DNAs contains random human genomic fragments maintained in a hamster background (human / hamster hybrid cell lines). These PCRs result in 93 scores indicating the presence or absence of the PCR product of the gene of interest. These scores are compared with scores created using PCR products from genomic sequences of known location. This comparison is conducted at <http://www.genome.wi.mit.edu/>.

The polynucleotide sequences of the present invention are also valuable tools for tissue expression studies. Such studies allow the determination of expression patterns of polynucleotides of the present invention which may give an indication as to the expression patterns of the encoded polypeptides in tissues, by detecting the mRNAs that encode them. The techniques used are well known in the art and include in situ hybridisation techniques to clones arrayed on a grid, such as cDNA microarray

hybridisation (Schena *et al*, Science, 270, 467-470, 1995 and Shalon *et al*, Genome Res, 6, 639-645, 1996) and nucleotide amplification techniques such as PCR. A preferred method uses the TAQMAN (Trade mark) technology available from Perkin Elmer. Results from these studies can provide an indication of the normal function of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by an alternative form of the same gene (for example, one having an alteration in polypeptide coding potential or a regulatory mutation) can provide valuable insights into the role of the polypeptides of the present invention, or that of inappropriate expression thereof in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

The polypeptides of the present invention are expressed in blood cells, cancer tissues, fetal liver, lymph nodes, placenta, spleen, trophoblast cells.

A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to produce antibodies that are immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic

mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies against polypeptides of the present invention may also be employed to treat diseases of the invention, amongst others.

Polypeptides and polynucleotides of the present invention may also be used as vaccines. Accordingly, in a further aspect, the present invention relates to a method for inducing an immunological response in a mammal that comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said animal from disease, whether that disease is already established within the individual or not. An immunological response in a mammal may also be induced by a method comprises delivering a polypeptide of the present invention via a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use as a vaccine, a polypeptide or a nucleic acid vector will be normally provided as a vaccine formulation (composition). The formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier

immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention have one or more biological functions that are of relevance in one or more disease states, in particular the diseases of the invention hereinbefore mentioned. It is therefore useful to identify compounds that stimulate or inhibit the function or level of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those that stimulate or inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections of chemical compounds, and natural product mixtures. Such agonists or antagonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; a structural or functional mimetic thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule.

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve measuring or detecting (qualitatively or quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (e.g. agonist or antagonist). Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring a heparanase-2 activity in the

mixture, and comparing the heparanase-2 activity of the mixture to a control mixture which contains no candidate compound.

Polypeptides of the present invention may be employed in conventional low capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well micotiter plates but also emerging methods such as the nanowell method described by Schullek et al, Anal Biochem., 246, 20-29, (1997).

Fusion proteins, such as those made from Fc portion and heparanase-2 polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

Screening techniques

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

A polypeptide of the present invention may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete

with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of antagonists of polypeptides of the present invention include antibodies or, in some cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

Screening methods may also involve the use of transgenic technology and heparanase-2 gene. The art of constructing transgenic animals is well established. For example, the heparanase-2 gene may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation embryos, or injection of genetically modified, such as by electroporation, embryonic stem cells into host blastocysts. Particularly useful transgenic animals are so-called "knock-in" animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in transgenic animals are useful in the drug discovery process, for target validation, where the compound is specific for the human target. Other useful transgenic animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous DNA sequence in a cell is partially or completely annulled. The gene knock-out may be targeted to specific cells or tissues, may occur only in certain cells or tissues as a consequence of the limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic animal technology also offers a whole animal expression-cloning system in which introduced genes are expressed to give large amounts of polypeptides of the present invention

Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:

- (a) a polypeptide of the present invention;
- (b) a recombinant cell expressing a polypeptide of the present invention;

(c) a cell membrane expressing a polypeptide of the present invention; or

(d) an antibody to a polypeptide of the present invention;

which polypeptide is preferably that of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

Glossary

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an

Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

"Polynucleotide" generally refers to any polyribonucleotide (RNA) or polydeoxynucleotide (DNA), which may be unmodified or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In

addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any polypeptide comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation,

gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, 1-12, in Post-translational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol, 182, 626-646, 1990, and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", Ann NY Acad Sci, 663, 48-62, 1992).

"Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequence of SEQ ID NO:1..

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A typical variant of a polynucleotide differs in nucleotide sequence from the reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from the reference polypeptide. Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allele, or it may be a

variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. Also included as variants are polypeptides having one or more post-translational modifications, for instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like. Embodiments include methylation of the N-terminal amino acid, phosphorylations of serines and threonines and modification of C-terminal glycines.

"Allele" refers to one of two or more alternative forms of a gene occurring at a given locus in the genome.

"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.

"Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A common primer is used in reverse complement to the polymorphism being assayed. This common primer can be between 50 and 1500 bps from the polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.

"Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

"Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by

comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.

5 "% Identity" - For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity
10 may be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

15 "Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of the sequences being compared (as for identity) but also, where there is
20 not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be determined.

25 Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the
30 programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147,195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the
35 best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide

sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP aligns two sequences, finding a "maximum similarity", according to the algorithm of Neddleman and Wunsch (J Mol Biol, 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, respectively. Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990, Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at www.ncbi.nlm.nih.gov) and FASTA (Pearson W R, Methods in Enzymology, 183, 63-99, 1990; Pearson W R and Lipman D J, Proc Nat Acad Sci USA, 85, 2444-2448, 1988, available as part of the Wisconsin Sequence Analysis Package).

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid sequences before comparison.

Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a polypeptide sequence, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.

"Identity Index" is a measure of sequence relatedness which may be used to compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence. Thus, for instance, a candidate polynucleotide sequence having, for example, an Identity Index of 0.95

10088675-032102

5 compared to a reference polynucleotide sequence is identical to the reference sequence except that the candidate polynucleotide sequence may include on average up to five differences per each 100 nucleotides of the reference sequence. Such differences are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference polynucleotide sequence, an average of up to 5 in every 100 of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

20 Similarly, for a polypeptide, a candidate polypeptide sequence having, for example, an Identity Index of 0.95 compared to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include an average of up to five differences per each 100 amino acids of the reference sequence. Such differences are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion. These differences may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polypeptide sequence having an Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

35 The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following equation:

$$n_a \leq x_a - (x_a \bullet I),$$

in which:

n_a is the number of nucleotide or amino acid differences,

x_a is the total number of nucleotides or amino acids in SEQ ID NO:1 or
5 SEQ ID NO:2, respectively,

I is the Identity Index ,

\bullet is the symbol for the multiplication operator, and

in which any non-integer product of x_a and I is rounded down to the
nearest integer prior to subtracting it from x_a .

10 "Homolog" is a generic term used in the art to indicate a polynucleotide or
polypeptide sequence possessing a high degree of sequence relatedness
to a reference sequence. Such relatedness may be quantified by
determining the degree of identity and/or similarity between the two
sequences as hereinbefore defined. Falling within this generic term are
15 the terms "ortholog", and "paralog". "Ortholog" refers to a polynucleotide
or polypeptide that is the functional equivalent of the polynucleotide or
polypeptide in another species. "Paralog" refers to a polynucleotide or
polypeptide that within the same species which is functionally similar.

20 "Fusion protein" refers to a protein encoded by two, unrelated, fused
genes or fragments thereof. Examples have been disclosed in US
5541087, 5726044. In the case of Fc-heparanase-2, employing an
immunoglobulin Fc region as a part of a fusion protein is advantageous
for performing the functional expression of Fc-heparanase-2 or fragments
of heparanase-2, to improve pharmacokinetic properties of such a fusion
25 protein when used for therapy and to generate a dimeric heparanase-2.
The Fc-heparanase-2 DNA construct comprises in 5' to 3' direction, a
secretion cassette, i.e. a signal sequence that triggers export from a
mammalian cell, DNA encoding an immunoglobulin Fc region fragment,
as a fusion partner, and a DNA encoding heparanase-2 or fragments
30 thereof. In some uses it would be desirable to be able to alter the intrinsic
functional properties (complement binding, Fc-Receptor binding) by
mutating the functional Fc sides while leaving the rest of the fusion
protein untouched or delete the Fc part completely after expression.

5 All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

Figures

Figure.1

10 Quantification of the relative in vivo expression of (Heparanase-2) Hep-2 using a real-time quantitative reverse transcription-polymerase chain reaction (Taq-Man).

Figure. 2

15 Hep-2 is expressed in various tumor tissue. A real-time quantitative reverse transcription-polymerase chain reaction was used to quantify the relative expression of Heparanase-2 (normalized to β -actin).

Figure. 3

Expression of Heparanase-2 (Hep-2) in 293 human kidney fibroblastys.

20 Western blot analysis using anti-V5-HRP antibodies. Lane1 (control), cell lysate of 293 cells transiently transfected with pcDNA3/TRAF-His; lane 2 (β -gal), cell lysate of 293 cells transiently transfected with pcDNA3.1/lacZ-V5-His; lane 3 (Hep-2), cell lysate of 293 cells transiently transfected with pcDNA3.1/Hep-2-V5-His.

Further examples

Example 1

RT-PCR

in vivo expression has been evaluate using real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR). As RT-PCR assay the Taq-Man fluorescence methodology (ABI PRISM 7700 Sequence detection system) was used. To quantify the relative expression of Heparanase-2 the upstream primer 5'-CCGATTCCTATGCTGCAGGA-3' and the downstream primer 5'- TCACGACATCAATGCCCTGA-3' and the fluorescence-labeled probe (6-carboxyfluorescein, 6-carboxy-tetramethyl-rhodamine);

5'CTTATGGTTGAACACTTTAGGAATGCTGGCC-3' have been used. All reactions were done in a 96 well-plate with 40 PCR-cycles (according ABI PRISM 7700 SDS). Typical used PCR-cycles: 1x 50°C 2min, 1x 95°C 10min, 40x 95°C and 15sec 60°C 1min.

The relative mRNA-expression was normalized to β -actin using the upstream primer 5'-ATTGCCGACAGGATGCAGAA-3', the downstream primer 5'-TTCCAGCAGATGTGGATCAGC-3' and the fluorescence-labeled probe (6-carboxyfluorescein, 6-carboxy-tetramethylrhodamine) 5'-CAAGATCATTGCTCCTCCTGAGCGCA-3'.

RNA and cDNA were obtained from Analytical Biological Services Inc. (aorta, bone marrow, colon, corpus C., lymph node, ovary, spinal cord, stomach), Clontech, Heidelberg, (brain, heart, kidney, skeletal muscle, testis, uterus, prostate, pancreas, liver) and Invitrogen, Netherland, (tumor tissue).

Example 2

Cloning and expression of Heparanase-2

The cDNA was generated from total prostate RNA (Clontech, Heidelberg) according to the SMART race cDNA amplification kit (#K1811-1, Clontech). Heparanase-2 DNA was amplified from the cDNA by the polymerase chain reaction (PCR) using the upstream primer1 5'-GCGAGACCCAGTAGGAAGAGAGG-3' and the downstream primer1 5'-CAGCAGGCCCACTGGTAGCCAT-3'.

Typical PCR-cycles :5 cycles 94°C 5 sec, 72°C 3min, 5 cycles 94°C 5 sec, 70°C 10sec, 72°C 3min, 20 cycles 94°C 5 sec, 68°C 10 sec, 72°C 3 min.

5 The PCR-product was further amplified using the upstream primer2 5'-ATGAGGGTGCTTTGTGCCTTCCC-3' and the downstream primer3 5'-TCGGTAGCGGCAGGCCAAAGCA-3' according to the SMART race cDNA amplification kit (#K1811-1, Clontech). Typical PCR-cycles: 25 cycles 94°C 5 sec, 68°C 10 sec, 72°C 3 min

10 The PCR fragment was cloned into pcDNA3.1/V5-His TOPO TA vector (#K4800-01, Invitrogen), sequenced using the BigDye-Kit (Applied Biosystems, Weiterstadt; ABI Prism 310 Genetic Analyzer) and used to transfect human 293 cells (ATCC, Rockville, Maryland) with the SuperFect transfection reagent (#301305, Quiagen) according to the protocol for transient transfection of adherent cells (Quiagen). After 24h
15 cells were lysed for 15 min in lysis buffer (50mM Tris pH 7,5; 10% NP40, 0,15% Deoxycholat, 1mM EDTA, 1µg/ml Aprotinin und Leupeptin, 1mM PMSF), centrifuged for 10 min at 20000xg and loaded on a Novex Mini-Gel (#EI0001, Invitrogen). After transfer on Nitrocellulose (X cell blot module #EI9051, Invitrogen) the expressed Hep-2-V5-His fusion protein
20 was detected using an anti-V5-HRP antibody (#R961-25, Invitrogen). A vector containing LacZ-V5-His (Invitrogen) and a pcDNA3/His vector containing TRAF (Acc.No. Q13077) were used as controls.

Example 3

25 Production of Heparanase-2

Cells expressing Heparanase with a C-terminal histidin tag were lysed in lysis buffer (20mM Tris pH 7,5; 150 mM NaCl, 1% TX-100, 0,25% NP40, 0,15% Deoxycholat, 1µg/ml Aprotinin, 1µg/ml Leupeptin, 1mM PMSF). The expressed protein was purified using chelators such as NTA or imido
30 acetic acid immobilized on a colum matrix and modified with metall ions such as Co, Ni, or Cu. The expressed protein was detected by western blotting method using anti-His6 antibody (Quiagen/ Invitrogen).

Example 4

Heparanase-2 activity

Heparanase activity can be measured toward fluorescein isothiocyanate (FITC)-heparan sulfate (HS). One milligrams of heparane sulfate (Sigma) and 1 mg of FITC (Molecular probes, Oregon) were dissolved in 200µl of 0,1 M sodium carbonate buffer, pH 9,5, and stirred overnight at 4 °C. The solution was then further loaded on a PD-10 desalting colum (Pharmacia) to isolate FITC-HS. The cell lysate (example2) was added to the reaction mixture (50mM sodium acetate, pH 4,2 containing FITC-HS) and incubated for 18h at 37°C. The reaction was stopped by the addition of Heparin (Sigma). The products of FITC-HS yielded by this reaction were analyzed by gel chromatography (Amersham Pharmacia).

Example 5

Production of Heparanase-2 specific antibodies

Heparanase-2 purified using PAGE electrophoresis (Laemmli, 1970) is used to immunize rabbits for the production of antibodies using standard protocols.

The amino acid sequence translated from Hep-2 is analyzed using DNASTar software (DNASTar Inc) to determine regions of high immunogenicity. Synthetic peptides have been synthesized (amino-acid sequence 156-169 (VALDK QKGCK IAQH), 249-262 (ASKKY NISWE LGNE), 505-518(HRSRK KIKLA GTLR)) and used to raise antibodies using standard protocols.

The oligopeptides are 15 residues in length, and coupled to keyhole limpet hemocyanin (KLH, Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS, Pierce). Rabbits are immunized with the oligopeptide-KLH complex in complete Freud's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to nitrocellulose, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with goat anti-rabbit-HRP (Biorad). High titered immune sera generated with the recombinant protein or synthetic peptide have been used to established ELISA technology and

Western blot technique to monitor and quantitate the recombinant protein. Generally antibodies of a given specificity have been pooled and precipitated with Ammonium-sulfate and dialysed against PBS. Selected sera have been biotinylated using the NHS-ester derivative of the biotin, available via Pierce. Biotinylation was performed according to the manufacturer. The antigens and the immunochemical techniques used to rise and characterize the polyclonal antibodies can easily be extended with protocols used for the production of monoclonal antibody specificities. The expert in this field would make his choice between a classical technique such as the hybridoma based technology or an antibody library based method according to his individual possibilities.

Example 6

Immuno-Assays for estimation of Heparanase-2

Specific sera raised with recombinant heparanase-2 have been used as a „catcher antibody“ for the coating of 96-well micro-titer plates (Nunc). 100 ml of the anti-Heparanase-2 serum (20µg/ml) has been used to coat plates over night. Prior to use, the plates have been washed three times with PBS and have been incubated for one hour with a BSA solution (1%) in order to prevent unspecific binding. Surplus of blocking solution has been removed and 100 µl of Heparanase-2 has been added in serial delutions and has been incubated for one hour. Plates have been washed three times prior to the application of the biotinylated anti-Heparanase-2 antibody for detection. After one hour, read-out has been performed via streptavidin-POD colour reaction with substrates such as ODB-tablets (Dako) measured at 490 nm.

Claims

1. An isolated polypeptide selected from one of the groups consisting of:

(a) an isolated polypeptide encoded by a polynucleotide comprising thesequence of SEQ ID NO:1;

(b) an isolated polypeptide comprising a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

(c) an isolated polypeptide having at least 95% identity to the polypeptide sequence of SEQ ID NO:2; and

(d) the polypeptide sequence of SEQ ID NO:2 and

(e) fragments and variants of such polypeptides in (a) to (d).

2. The isolated polypeptide as claimed in claim 1 comprising the polypeptide sequence of SEQ ID NO:2.

3. The isolated polypeptide as claimed in claim 1 which is the polypeptide sequence of SEQ ID NO:2.

4. An isolated polynucleotide selected from one of the groups consisting of:

(a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95% identity to the polynucleotide sequence of SEQ ID NO:1;

(b) an isolated polynucleotide having at least 95% identity to the polynucleotide of SEQ ID NO:1;

(c) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

(d) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95% identity to the polypeptide sequence of SEQ ID NO:2;

(e) an isolated polynucleotide with a nucleotide sequence of at least 100 nucleotides obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof having at least 15 nucleotides;

5 (f) a polynucleotide which is the RNA equivalent of a polynucleotide of (a) to (e);

or a polynucleotide sequence complementary to said isolated polynucleotide

10 and polynucleotides that are variants and fragments of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

5. An isolated polynucleotide as claimed in claim 4 selected from the group consisting of:

15 (a) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1;

(b) the isolated polynucleotide of SEQ ID NO:1;

(c) an isolated polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2; and

20 (d) an isolated polynucleotide encoding the polypeptide of SEQ ID NO:2.

6. An expression system comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell.

25 7. A recombinant host cell comprising the expression vector of claim 6 or a membrane thereof expressing the polypeptide of claim 1.

8. A process for producing a polypeptide of claim 1 comprising the step of culturing a host cell as defined in claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

5

9. A fusion protein consisting of the Immunoglobulin Fc-region and any one polypeptide of claim 1.

10. An antibody immunospecific for the polypeptide of any one of claims 1 to 3.

10

11. A method for screening to identify compounds that stimulate or inhibit the function or level of the polypeptide of claim 1 comprising a method selected from the group consisting of:

15

(a) measuring or, detecting, quantitatively or qualitatively, the binding of a candidate compound to the polypeptide (or to the cells or membranes expressing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;

(b) measuring the competition of binding of a candidate compound to the polypeptide (or to the cells or membranes expressing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor;

20

(c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes expressing the polypeptide;

25

(d) mixing a candidate compound with a solution containing a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a control mixture which contains no candidate compound; or

(e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide or said polypeptide in cells, using for instance, an ELISA assay, and

30

(f) producing said compound according to biotechnological or chemical standard techniques.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number
WO 01/21814 A1

(51) International Patent Classification⁷: C12N 15/56,
15/62, 9/24, C07K 16/40, C12Q 1/68, A61K 38/47, 48/00,
G01N 33/50

(72) Inventors; and
(75) Inventors/Applicants (for US only): DÜCKER, Klaus
[DE/DE]; Ettesterstrasse 5, 64291 Darmstadt (DE). SIR-
RENBURG, Christian [DE/DE]; Heinrich-Delp-Strasse
221, 64297 Darmstadt (DE).

(21) International Application Number: PCT/EP00/08837

(22) International Filing Date:
11 September 2000 (11.09.2000)

(74) Common Representative: MERCK PATENT GMBH;
64271 Darmstadt (DE).

(25) Filing Language: English

(81) Designated States (national): CA, JP, US.

(26) Publication Language: English

(84) Designated States (regional): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).


(30) Priority Data:
99118805.3 23 September 1999 (23.09.1999) EP
00114649.7 7 July 2000 (07.07.2000) EP

Published:
— With international search report.

(71) Applicant (for all designated States except US): MERCK
PATENT GMBH [DE/DE]; Frankfurter Strasse 250,
64293 Darmstadt (DE).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: HEPARANASE-2, A MEMBER OF THE HEPARANASE PROTEIN FAMILY



(57) Abstract: Heparanase-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing heparanase-2 polypeptides and polynucleotides in diagnostic assays.

1 / 2

Fig. 1






Fig. 2



2/2

Fig. 3



Docket No. Merck

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A novel member of the Heparanase protein family

the specification of which

(check one)

- ☐ is attached hereto.
- ☒ was filed on _____ as United States Application No. or PCT International Application Number _____ and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

<u>99118805.3</u> (Number)	<u>EP</u> (Country)	<u>23.09.99</u> (Day/Month/Year Filed)	<input type="checkbox"/>
<u>00114649</u> (Number)	<u>EP</u> (Country)	<u>07.07.00</u> (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States of PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112. I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C.F.R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint

I. William Millen (Reg. No. 19,544)
 John L. White (Reg. No. 17,746)
 Anthony J. Zelano (Reg. No. 27,969)
 Alan E. J. Branigan (Reg. No. 20,565)
 John R. Moses (Reg. No. 24,983)
 Harry B. Shubin (Reg. No. 32,004)
 Brion P. Heaney (Reg. No. 32,542)
 Richard J. Traverso (Reg. No. 30,595)

John A. Sopp (Reg. No. 33,103)
 Richard M. Lebovitz (Reg. No. 37,067)
 John H. Thomas (Reg. No. 33,460)
 Catherine M. Joyce (Reg. No. 40,668)
 James T. Moore (Reg. No. 35,649)
 James E. Ruland (Reg. No. 37,432)
 Nancy Axelrod (Reg. No. 44,014)
 Jennifer J. Branigan (Reg. No. 40,921)

to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Send Correspondence to: MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza I
2200 Clarendon Blvd., Suite 1400
Arlington, VA 22201

Direct Telephone Calls to: (name and telephone number)

Full name of sole or first inventor	
<u>Klaus Dücker</u>	
Sole or first inventor's	Date
<u>[Signature]</u>	<u>23. JAN 2002</u>
Residence	
<u>Ettesterstr. 5, 64291 Darmstadt, Germany</u> <u>DEX</u>	
Citizenship	
<u>German</u>	
Post Office Address	
<u>c/o MERCK KGaA; 64271 Darmstadt, Germany</u>	

Full name of second inventor, if any	
<u>Christian Sirrenberg</u>	
Second inventor's signature	Date
<u>[Signature]</u>	<u>23. JAN 2002</u>
Residence	
<u>Heinrich Delp-Str. 221, 64297 Darmstadt, Germany</u> <u>DEX</u>	
Citizenship	
<u>German</u>	
Post Office Address	
<u>c/o MERCK KGaA; 64271 Darmstadt, Germany</u>	

SEQUENCE LISTING

SEQUENCE LISTING

5 <110> Merck Patent GmbH

<120> Novel heparanase

<130> HSPnaseKDWS

10 <140>

<141>

<160> 15

15 <170> PatentIn Ver. 2.1

<210> 1

<211> 1779

20 <212> DNA

<213> Homo sapiens

<220>

<221> CDS

25 <222> (1)..(1779)

<400> 1

atg agg gtg ctt tgt gcc ttc cct gaa gcc atg ccc tcc agc aac tcc	48
Met Arg Val Leu Cys Ala Phe Pro Glu Ala Met Pro Ser Ser Asn Ser	
30 1 5 10 15	
cgc ccc ccc gcg tgc cta gcc ccg ggg gct ctc tac ttg gct ctg ttg	96
Arg Pro Pro Ala Cys Leu Ala Pro Gly Ala Leu Tyr Leu Ala Leu Leu	
20 25 30	
35 ctc cat ctc tcc ctt tcc tcc cag gct gga gac agg aga ccc ttg cct	144
Leu His Leu Ser Leu Ser Ser Gln Ala Gly Asp Arg Arg Pro Leu Pro	
35 40 45	
40 gta gac aga gct gca ggt ttg aag gaa aag acc ctg att cta ctt gat	192
Val Asp Arg Ala Ala Gly Leu Lys Glu Lys Thr Leu Ile Leu Leu Asp	
50 55 60	
gtg agc acc aag aac cca gtc agg aca gtc aat gag aac ttc ctc tct	240
Val Ser Thr Lys Asn Pro Val Arg Thr Val Asn Glu Asn Phe Leu Ser	
65 70 75 80	
ctg cag ctg gat ccg tcc atc att cat gat ggc tgg ctc gat ttc cta	288
Leu Gln Leu Asp Pro Ser Ile Ile His Asp Gly Trp Leu Asp Phe Leu	
50 85 90 95	
agc tcc aag cgc ttg gtg acc ctg gcc ccg gga ctt tcg ccc gcc ttt	336
Ser Ser Lys Arg Leu Val Thr Leu Ala Arg Gly Leu Ser Pro Ala Phe	
100 105 110	
55 ctg cgc ttc ggg ggc aaa agg acc gac ttc ctg cag ttc cag aac ctg	384
Leu Arg Phe Gly Gly Lys Arg Thr Asp Phe Leu Gln Phe Gln Asn Leu	
115 120 125	
60 agg aac ccg gcg aaa agc cgc ggg ggc ccg ggc ccg gat tac tat ctc	432

10088676-0001

	Arg	Asn	Pro	Ala	Lys	Ser	Arg	Gly	Gly	Pro	Gly	Pro	Asp	Tyr	Tyr	Leu	
	130						135				140						
5	aaa	aac	tat	gag	gat	gac	att	gtt	cga	agt	gat	gtt	gcc	tta	gat	aaa	480
	Lys	Asn	Tyr	Glu	Asp	Asp	Ile	Val	Arg	Ser	Asp	Val	Ala	Leu	Asp	Lys	
	145					150					155					160	
10	cag	aaa	ggc	tgc	aag	att	gcc	cag	cac	cct	gat	gtt	atg	ctg	gtg	ctc	528
	Gln	Lys	Gly	Cys	Lys	Ile	Ala	Gln	His	Pro	Asp	Val	Met	Leu	Val	Leu	
					165					170					175		
15	caa	agg	gag	aag	gca	gct	cag	atg	cat	ctg	gtt	ctt	cta	aag	gag	caa	576
	Gln	Arg	Glu	Lys	Ala	Ala	Gln	Met	His	Leu	Val	Leu	Leu	Lys	Glu	Gln	
				180					185					190			
20	ttc	tcc	aat	act	tac	agt	aat	ctc	ata	tta	aca	gcc	agg	tct	cta	gac	624
	Phe	Ser	Asn	Thr	Tyr	Ser	Asn	Leu	Ile	Leu	Thr	Ala	Arg	Ser	Leu	Asp	
			195					200					205				
25	aaa	ctt	tat	aac	ttt	gct	gat	tgc	tct	gga	ctc	cac	ctg	ata	ttt	gct	672
	Lys	Leu	Tyr	Asn	Phe	Ala	Asp	Cys	Ser	Gly	Leu	His	Leu	Ile	Phe	Ala	
		210					215					220					
30	cta	aat	gca	ctg	cgt	cgt	aat	ccc	aat	aac	tcc	tgg	aac	agt	tct	agt	720
	Leu	Asn	Ala	Leu	Arg	Arg	Asn	Pro	Asn	Asn	Ser	Trp	Asn	Ser	Ser	Ser	
	225					230					235					240	
35	gcc	ctg	agt	ctg	ttg	aag	tac	agc	gcc	agc	aaa	aag	tac	aac	att	tct	768
	Ala	Leu	Ser	Leu	Leu	Lys	Tyr	Ser	Ala	Ser	Lys	Lys	Tyr	Asn	Ile	Ser	
					245				250						255		
40	tgg	gaa	ctg	ggt	aat	gag	cca	aat	aac	tat	cgg	acc	atg	cat	ggc	cgg	816
	Trp	Glu	Leu	Gly	Asn	Glu	Pro	Asn	Asn	Tyr	Arg	Thr	Met	His	Gly	Arg	
				260					265					270			
45	gca	gta	aat	ggc	agc	cag	ttg	gga	aag	gat	tac	atc	cag	ctg	aag	agc	864
	Ala	Val	Asn	Gly	Ser	Gln	Leu	Gly	Lys	Asp	Tyr	Ile	Gln	Leu	Lys	Ser	
			275					280					285				
50	ctg	ttg	cag	ccc	atc	cgg	att	tat	tcc	aga	gcc	agc	tta	tat	ggc	cct	912
	Leu	Leu	Gln	Pro	Ile	Arg	Ile	Tyr	Ser	Arg	Ala	Ser	Leu	Tyr	Gly	Pro	
		290					295					300					
55	aat	att	ggg	cgg	ccg	agg	aag	aat	gtc	atc	gcc	ctc	cta	gat	gga	ttc	960
	Asn	Ile	Gly	Arg	Pro	Arg	Lys	Asn	Val	Ile	Ala	Leu	Leu	Asp	Gly	Phe	
	305					310					315					320	
60	atg	aag	gtg	gca	gga	agt	aca	gta	gat	gca	gtt	acc	tgg	caa	cat	tgc	1008
	Met	Lys	Val	Ala	Gly	Ser	Thr	Val	Asp	Ala	Val	Thr	Trp	Gln	His	Cys	
					325					330					335		
65	t																

	370	375	380	
5	acc tca gct gga ggc Thr Ser Ala Gly Gly 385	aca aac aat cta Thr Asn Asn Leu 390	tcc gat tcc tat gct gca gga Ser Asp Ser Tyr Ala Ala Gly 395	1200
10	ttc tta tgg ttg Phe Leu Trp Leu 405	aac act tta gga atg Asn Thr Leu Gly Met 410	ctg gcc aat cag ggc att gat Leu Ala Asn Gln Gly Ile Asp 415	1248
15	gtc gtg ata cgg cac Val Val Ile Arg His 420	tca ttt ttt gac cat Ser Phe Phe Asp His 425	gga tac aat cac ctc gtg Gly Tyr Asn His Leu Val 430	1296
20	gac cag aat ttt aac Asp Gln Asn Phe Asn 435	cca tta cca gac tac Pro Leu Pro Asp Tyr 440	tgg ctc tct ctc ctc tac Trp Leu Ser Leu Leu Tyr 445	1344
25	aag cgc ctg atc ggc Lys Arg Leu Ile Gly 450	ccc aaa gtc ttg gct Pro Lys Val Leu Ala 455	gtg cat gtg gct ggg ctc Val His Val Ala Gly Leu 460	1392
30	cag cgg aag cca cgg Gln Arg Lys Pro Arg 465	cct ggc cga gtg atc Pro Gly Arg Val Ile 470	cgg gac aaa cta agg att Arg Asp Lys Leu Arg Ile 475	1440
35	tat gct cac tgc aca Tyr Ala His Cys Thr 485	aac cac cac aac cac Asn His His Asn His 490	aac tac gtt cgt ggg tcc Asn Tyr Val Arg Gly Ser 495	1488
40	att aca ctt ttt atc Ile Thr Leu Phe Ile 500	atc aac ttg cat cga Ile Asn Leu His Arg 505	tca aga aag aaa atc aag Ser Arg Lys Lys Ile Lys 510	1536
45	ctg gct ggg act ctc Leu Ala Gly Thr Leu 515	aga gac aag ctg gtt Arg Asp Lys Leu Val 520	cac cag tac ctg ctg cag His Gln Tyr Leu Leu Gln 525	1584
50	ccc tat ggg cag gag Pro Tyr Gly Gln Glu 530	ggc cta aag tcc aag Gly Leu Lys Ser Lys 535	tca gtg caa ctg aat ggc Ser Val Gln Leu Asn Gly 540	1632
55	cag ccc tta gtg atg Gln Pro Leu Val Met 545	gtg gac gac ggg acc Val Asp Asp Gly Thr 550	ctc cca gaa ttg aag ccc Leu Pro Glu Leu Lys Pro 555	1680
60	cgc ccc ctt cgg gcc Arg Pro Leu Arg Ala 565	ggc cgg aca ttg gtc Gly Arg Thr Leu Val 570	atc cct cca gtc acc atg Ile Pro Pro Val Thr Met 575	1728
65	ggc ttt tat gtg gtc Gly Phe Tyr Val Val 580	aag aat gtc aat gct Lys Asn Val Asn Ala 585	ttg gcc tgc cgc tac cga Leu Ala Cys Arg Tyr Arg 590	1776
70	taa			1779
75	<210> 2			
80	<211> 592			
85	<212> PRT			

$\langle 400 \rangle$ 2

5	Met	Arg	Val	Leu	Cys	Ala	Phe	Pro	Glu	Ala	Met	Pro	Ser	Ser	Asn	Ser
	1				5				10						15	
	Arg	Pro	Pro	Ala	Cys	Leu	Ala	Pro	Gly	Ala	Leu	Tyr	Leu	Ala	Leu	Leu
			20						25					30		
	Leu	His	Leu	Ser	Leu	Ser	Ser	Gln	Ala	Gly	Asp	Arg	Arg	Pro	Leu	Pro
		35						40					45			
10	Val	Asp	Arg	Ala	Ala	Gly	Leu	Lys	Glu	Lys	Thr	Leu	Ile	Leu	Leu	Asp
	50						55					60				
	Val	Ser	Thr	Lys	Asn	Pro	Val	Arg	Thr	Val	Asn	Glu	Asn	Phe	Leu	Ser
	65				70					75					80	
	Leu	Gln	Leu	Asp	Pro	Ser	Ile	Ile	His	Asp	Gly	Trp	Leu	Asp	Phe	Leu
15					85					90					95	
	Ser	Ser	Lys	Arg	Leu	Val	Thr	Leu	Ala	Arg	Gly	Leu	Ser	Pro	Ala	Phe
				100					105					110		
	Leu	Arg	Phe	Gly	Gly	Lys	Arg	Thr	Asp	Phe	Leu	Gln	Phe	Gln	Asn	Leu
			115					120					125			
20	Arg	Asn	Pro	Ala	Lys	Ser	Arg	Gly	Gly	Pro	Gly	Pro	Asp	Tyr	Tyr	Leu
	130						135					140				
	Lys	Asn	Tyr	Glu	Asp	Asp	Ile	Val	Arg	Ser	Asp	Val	Ala	Leu	Asp	Lys
	145				150						155				160	
25	Gln	Lys	Gly	Cys	Lys	Ile	Ala	Gln	His	Pro	Asp	Val	Met	Leu	Val	Leu
				165						170					175	
	Gln	Arg	Glu	Lys	Ala	Ala	Gln	Met	His	Leu	Val	Leu	Leu	Lys	Glu	Gln
				180					185					190		
	Phe	Ser	Asn	Thr	Tyr	Ser	Asn	Leu	Ile	Leu	Thr	Ala	Arg	Ser	Leu	Asp
			195				200						205			
30	Lys	Leu	Tyr	Asn	Phe	Ala	Asp	Cys	Ser	Gly	Leu	His	Leu	Ile	Phe	Ala
	210						215					220				
	Leu	Asn	Ala	Leu	Arg	Arg	Asn	Pro	Asn	Asn	Ser	Trp	Asn	Ser	Ser	Ser
	225				230						235				240	
35	Ala	Leu	Ser	Leu	Leu	Lys	Tyr	Ser	Ala	Ser	Lys	Lys	Tyr	Asn	Ile	Ser
				245						250					255	
	Trp	Glu	Leu	Gly	Asn	Glu	Pro	Asn	Asn	Tyr	Arg	Thr	Met	His	Gly	Arg
				260					265					270		
	Ala	Val	Asn	Gly	Ser	Gln	Leu	Gly	Lys	Asp	Tyr	Ile	Gln	Leu	Lys	Ser
			275					280					285			
40	Leu	Leu	Gln	Pro	Ile	Arg	Ile	Tyr	Ser	Arg	Ala	Ser	Leu	Tyr	Gly	Pro
	290						295					300				
	Asn	Ile	Gly	Arg	Pro	Arg	Lys	Asn	Val	Ile	Ala	Leu	Leu	Asp	Gly	Phe
	305					310					315				320	
45	Met	Lys	Val	Ala	Gly	Ser	Thr	Val	Asp	Ala	Val	Thr	Trp	Gln	His	Cys
				325			</									

```

20      <210> 3
        <211> 20
        <212> DNA
        <213> Artificial Sequence

25      <220>
        <223> Description of Artificial Sequence: RT PCR Primer1

        <400> 3
        ccgattccta tgctgcagga
30
        <210> 4
        <211> 20
        <212> DNA
35      <213> Artificial Sequence

        <220>
        <223> Description of Artificial Sequence: RT PCR Primer2

40      <400> 4
        tcacgacatc aatgccctga
        20

        <210> 5
45      <211> 31
        <212> DNA
        <213> Artificial Sequence

        <220>
50      <223> Description of Artificial Sequence: Labeled probe1

        <400> 5
        cttatgggttg aacacttttag gaatgctggc c
        31

55      <210> 6
        <211> 20
        <212> DNA
        <213> Artificial Sequence

60      <220>

```

<223> Description of Artificial Sequence: PT PCR Primer3

<400> 6
attgccgaca ggatgcagaa 20

5

<210> 7
<211> 21
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: RT PCR Primer4

15 <400> 7
ttccagcaga tgtggatcag c 21

<210> 8
20 <211> 26
<212> DNA
<213> Artificial Sequence

<220>
25 <223> Description of Artificial Sequence: Labeled Probe2

<400> 8
caagatcatt gctcctcctg agcgca 26

30

<210> 9
<211> 23
<212> DNA
<213> Artificial Sequence

35

<220>
<223> Description of Artificial Sequence: Upstream
Primer5

40 <400> 9
gcgagaccca gtaggaagag agg 23

<210> 10
45 <211> 22
<212> DNA
<213> Artificial Sequence

<220>
50 <223> Description of Artificial Sequence: Downstream
Primer6

<400> 10
cagcaggccc actggtagcc at 22

55

<210> 11
<211> 23
<212> DNA
60 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Upstream
Primer7

5 <400> 11
atgagggtgc tttgtgcctt ccc 23

<210> 12
10 <211> 22
<212> DNA
<213> Artificial Sequence

<220>
15 <223> Description of Artificial Sequence: Downstream
Primer8

<400> 12
20 tcggtagcgg caggccaaag ca 22

<210> 13
<211> 14
<212> PRT
25 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide 1

30 <400> 13
Val Ala Leu Asp Lys Gln Lys Gly Cys Lys Ile Ala Gln His
1 5 10

35 <210> 14
<211> 14
<212> PRT
<213> Artificial Sequence

40 <220>
<223> Description of Artificial Sequence: Peptide 2

<400> 14
Ala Ser Lys Lys Tyr Asn Ile Ser Trp Glu Leu Gly Asn Glu
45 1 5 10

<210> 15
<211> 14
50 <212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide 3

55 <400> 15
His Arg Ser Arg Lys Lys Ile Lys Leu Ala Gly Thr Leu Arg
1 5 10